Literature DB >> 15145240

Subclinical Cushing's syndrome in adrenal incidentalomas.

Rebecca S Sippel1, Herbert Chen.   

Abstract

Up to 20% of patients with adrenal incidentalomas have abnormal cortisol production, and can be classified as having subclinical Cushing's syndrome. Although these tumors do not secrete enough cortisol to lead to the development of overt Cushing's syndrome, they are likely playing a contributory role in the development of hypertension, diabetes, osteoporosis, and obesity. Studies suggest that many of these problems can be reversed with surgical treatment. Additionally, if this diagnosis is not sought out before pursuing an adrenalectomy for an incidentaloma, the patient can develop profound postoperative adrenal insufficiency.

Entities:  

Mesh:

Year:  2004        PMID: 15145240     DOI: 10.1016/j.suc.2004.01.001

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  14 in total

1.  Management of adrenal incidentaloma by laparoscopic transperitoneal anterior and submesocolic approach.

Authors:  Alessandro M Paganini; Mario Guerrieri; Andrea Balla; Silvia Quaresima; Andrea M Isidori; Franco Iafrate; Giancarlo D'Ambrosio; Giovanni Lezoche; Emanuele Lezoche
Journal:  Langenbecks Arch Surg       Date:  2015-12-18       Impact factor: 3.445

2.  Primary adrenal hypercortisolism: minimally invasive surgical treatment or medical therapy? A retrospective study with long-term follow-up evaluation.

Authors:  Mario Guerrieri; Roberto Campagnacci; Andrea Patrizi; Chiara Romiti; Giorgio Arnaldi; Marco Boscaro
Journal:  Surg Endosc       Date:  2010-03-25       Impact factor: 4.584

3.  Increased ratio of mRNA expression of the genes CYP17 and CYP11B1 indicates autonomous cortisol production in adrenocortical tumors.

Authors:  U Enberg; J Hennings; C Volpe; P Hellman; A Höög; B Hamberger; M Thorén
Journal:  J Endocrinol Invest       Date:  2009-06-24       Impact factor: 4.256

4.  Guess the case from the ochsner clinic.

Authors:  Russell E Brown; Marideli C Scanlan; Alan L Burshell; William S Richardson
Journal:  Ochsner J       Date:  2007

5.  The role of adrenal scintigraphy in the diagnosis of subclinical Cushing's syndrome and the prediction of post-surgical hypoadrenalism.

Authors:  Maria Pia Ricciato; Vincenzo Di Donna; Germano Perotti; Alfredo Pontecorvi; Rocco Bellantone; Salvatore M Corsello
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

6.  Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery.

Authors:  Yeşim Erbil; Evin Ademoğlu; Neşe Ozbey; Umut Barbaros; Burcu Tulumoğlu Yanik; Artur Salmaslioğlu; Alp Bozbora; Selçuk Ozarmağan
Journal:  World J Surg       Date:  2006-09       Impact factor: 3.352

7.  Predictive value of retroperitoneal fat area measurement for detecting metabolic syndrome in patients undergoing adrenalectomy.

Authors:  Feyzullah Ersöz; Yeşim Erbil; Serkan Sarı; Artür Salmaslıoğlu; Halim Işsever; Ferihan Aral; Selçuk Özarmağan
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

8.  Unrecognized adrenal insufficiency in patients undergoing laparoscopic adrenalectomy.

Authors:  Jamie Mitchell; German Barbosa; Michael Tsinberg; Mira Milas; Allan Siperstein; Eren Berber
Journal:  Surg Endosc       Date:  2008-11-27       Impact factor: 4.584

Review 9.  Surgery for Cushing's syndrome: an historical review and recent ten-year experience.

Authors:  John R Porterfield; Geoffrey B Thompson; William F Young; John T Chow; Raymond S Fryrear; Jon A van Heerden; David R Farley; John L D Atkinson; Fredric B Meyer; Charles F Abboud; Todd B Nippoldt; Neena Natt; Dana Erickson; Adrian Vella; Paul C Carpenter; Melanie Richards; J Aidan Carney; Dirk Larson; Cathy Schleck; Marilyn Churchward; Clive S Grant
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

10.  Adrenal incidentaloma: surgical update.

Authors:  M Guerrieri; A De Sanctis; F Crosta; G Arnaldi; M Boscaro; G Lezoche; R Campagnacci
Journal:  J Endocrinol Invest       Date:  2007-03       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.